Premium
Outcomes of pharmacological management of nocturia with non‐antidiuretic agents: does statistically significant equal clinically significant?
Author(s) -
Smith Ariana L.,
Wein Alan J.
Publication year - 2011
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09972.x
Subject(s) - nocturia , medicine , overactive bladder , urology , antidiuretic , clinical efficacy , benign prostatic hyperplasia (bph) , gynecology , urinary system , prostate , hormone , pathology , alternative medicine , cancer
OBJECTIVE • To evaluate the statistical and clinical efficacy of the pharmacological treatments of nocturia using non‐antidiuretic agents. PATIENTS AND METHODS • A literature review of treatments of nocturia specifically addressing the impact of alpha blockers, 5‐alpha reductase inhibitors (5ARI) and antimuscarinics on reduction in nocturnal voids. RESULTS • Despite commonly reported statistically significant results, nocturia has shown a poor clinical response to traditional therapies for benign prostatic hyperplasia including alpha blockers and 5ARI. • Similarly, nocturia has shown a poor clinical response to traditional therapies for overactive bladder including antimuscarinics. CONCLUSIONS • Statistical success has been achieved in some groups with a variety of alpha blockers and antimuscarinic agents, but the clinical significance of these changes is doubtful. • It is likely that other types of therapy will need to be employed in order to achieve a clinically significant reduction in nocturia.